BioSpace News Archive

Teva Announces U.S. Launch of Autoinjector for AJOVY ® (fremanezumab-vfrm) Injection

VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters’ option to purchase additional shares.

Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC) and Alzheimer’s Disease, today announced that it has closed a private placement of its securities with a group of accredited investors that included several directors of the Company and members of management. Investors in the private placement purch

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for its investigational drug mobocertinib (TAK-788) for the treatment of patients with metastatic non-sma

Enumeration of Circulating Endothelial Cells (CECs) with CELLSEARCH platform may offer a new tool for investigating the role of the damaged endothelium in SARS-CoV-2 infection and clinical manifestation BOLOGNA, Italy , April 27, 2020 /PRNewswire/ -- Menarini Silicon Biosystems, a global leader in liquid biopsy and rare cells technologies, today announces that it is expl

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention, today announced that it will release financial results for the quarter ended March 31, 2020 after the market closes on Monday, May 11, 2020. Ron Rocca, President and Chief Executive Officer, and Kamal Adawi,

Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that it will report first quarter 2020 financial results on Wednesday, May 6, 2020, prior to the open of the market. The announcement will be followed by a live audio webcast and confer

Abstracts accepted for presentation in oral and poster sessions at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting Treatment with relugolix combination therapy resulted in significant improvements in pain and quality of life in women with heavy menstrual bleeding associated with uterine fibroids Relugolix combination therapy preserved bone mineral density over 24 weeks compared with relugolix monotherapy BASEL, Switzerland, Ap

Arcutis Biotherapeutics, Inc . (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that Halley E. Gilbert has been appointed to the Arcutis Board of Directors effective May 1, 2020. “We are thrilled to welcome Halley to the Arcutis Board,” said Frank Watanabe ,

Quest Products, LLC introduces a new nasal filter designed for people interested in protection against the smallest of airborne particles and pollutants. Its unique filtration material is electrostatically charged to better capture microscopic particles and protect people from droplets released during coughing and sneezing